Avtor/Urednik		Takač, Iztok
Naslov		Research work at the Department of gynecologic and breast oncology of Maribor teaching hospital
Tip		članek
Vir		In: Takač I, editor. Proceedings of the exchange programme of trainees in obstetrics and gynaecology at Maribor teaching hospital; 2004 Nov 22-25; Maribor. Maribor: Splošna bolnišnica Maribor,
Leto izdaje		2004
Obseg		str. 63-76
Jezik		eng
Abstrakt		A comprehensive research work has been established at the Department of Gynecologic and Breast Oncology of Maribor Teaching Hospital. Among the most important recently conducted studies are a multinational study in patients with ovarian carcinoma using the HMFG1 antibody labeled with 90Yttrium (R1549), (study code: SMART), a multi-national randomized Phase 111 GCIG Intergroup Study comparing 1st line chemotherapy with Gemcitabine, Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in previously untreated patients with epithelia( ovarian cancer FIGO stages I - IV (study code OVAR-9), a multicenter phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC-->T) as adjuvant treatment of operable breast cancer Her2neu negative patients with positive axillary lymph nodes (study code BCIRG 005) and a multicenter phase 111 randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) and with docetaxel, carboplatin and trastuzumab (TCH) in the adjuvant treatment of node positive and high risk node negative patients with operable breast cancer containing the her2neu alteration (study code BCIRG 006). All of these are very important multicentric and multiinstitutional studies in which several patients have been enrolled.
Deskriptorji		OVARIAN NEOPLASMS ANTIBODIES, MONOCLONAL CA-15-3 ANTIGEN ANTINEOPLASTIC AGENTS, COMBINED BREAST NEOPLASMS RADIOIMMUNOTHERAPY PACLITAXEL DISEASE-FREE SURVIVAL TREATMENT OUTCOME